GDDs significantly increase corneal edema risk compared to trabeculectomy, with a 27.7% incidence versus 13.5% for trabeculectomy. MIGS and Xen stents show lower risks for corneal edema, with ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a ...
Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AURN001 is an allogeneic cell therapy being evaluated ...
Findings from a pioneering study in The American Journal of Pathology, published by Elsevier, reveal that administration of the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes corneal ...
Findings from a study in The American Journal of Pathology reveal that administration of the neuropeptide α-melanocyte–stimulating hormone (α-MSH) promotes corneal healing and restores normal eye ...
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population ...
Researchers at Harvard Medical School have demonstrated the potent therapeutic effects of administration of the neuropeptide α-melanocyte–stimulating hormone (α-MSH) through melanocortin receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results